

Anesthetic and Life Support Drugs Advisory Committee Meeting
September 9-10, 2003
Holiday Inn
Bethesda, Maryland

TABLE of CONTENTS

Executive Summary Memo	Tab 1
Concept Paper: Risk Management Programs	Tab 2
Abuse Liability and Drug Scheduling: The Role of the FDA	Tab 3
CSS Abuse Liability Analysis of Palladone (hydromorphone HCl) Extended Release Capsules	Tab 4
<ul style="list-style-type: none">• Palladone XL (Canadian Approved Label)• Hydromorphone Hydrochloride BNF• Progress Report from the Clinical Pharmacology Section of the NIDA Research Center• Comparing the Subjective, Psychomotor, and Physiological Effects of Intravenous Hydromorphone and Morphine in Healthy Volunteers (Hill and Zacny, 2000)	
Substance Abuse and Mental Health Services Administration	Tab 5
<ul style="list-style-type: none">• Nonmedical Pain Reliever Use Data from the National Survey on Drug Use and Health• Drug Abuse Warning Network• Treatment Episode Data Set	
Reference Documents and Literature	Tab 6
<ul style="list-style-type: none">• DEA – Information of the Controlled Substances Act• Consensus Document – The American Academy of Pain Medicine, The American Pain Society, and the American Society of Addiction Medicine – Definitions Related to the Use of Opioids for the Treatment of Pain• CPDD Taskforce on Prescription Opioid Non-medical Use and Abuse: Position Statement• FSMB – Model Guidelines for the Use of Controlled Substances for the Treatment of Pain• Role of Urine Toxicology Testing in the Management of Chronic Opioid Therapy (Katz and Fanciullo, 2002)• Opioids for Chronic Nonmalignant Pain (Choosing Suitable Candidates for Long-term Therapy (Belgrade, 1999)	

Anesthetic and Life Support Drugs Advisory Committee Meeting
September 9-10, 2003
Holiday Inn
Bethesda, Maryland

TABLE of CONTENTS

	<i>Tab 6 continued</i>
<ul style="list-style-type: none">• Prevalence and Characteristics of Chronic Pain Among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities (Rosenblum <i>et al.</i>, 2003)• Prescription Drug Abuse: FDA and SAMHSA Join Forces	
 Risk Management Programs	Tab 7
<ul style="list-style-type: none">• Actiq (oral transmucosal fentanyl citrate)• Subutex (buprenorphine HCl) and Suboxone (buprenorphine HCl/naloxone)	
 Patient Package Inserts	Tab 8
<ul style="list-style-type: none">• Actiq• Oxycontin• Avinza• Subutex and Suboxone	
 Executive Summary: Prescription Monitoring Work Groups of the National Alliance for Model State Drug Laws	Tab 9
 Prescription Drugs: State Monitoring Programs Provide Useful Tool To Reduce Diversion (May 2002)	Tab 10
 Prescription Monitoring Work Group of the National Alliance for Model State Drug Law (February 2002)	Tab 11